Reviewing Demant A/S (OTCMKTS:WILYY) & Flora Growth (NASDAQ:FLGC)

Demant A/S (OTCMKTS:WILYY) and Flora Growth (NASDAQ:FLGC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations for Demant A/S and Flora Growth, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Demant A/S	0	1	0	2	3.33
Flora Growth	1	0	1	0	2.00

Flora Growth has a consensus price target of $30.00, indicating a potential upside of 300.53%. Given Flora Growth’s higher possible upside, analysts clearly believe Flora Growth is more favorable than Demant A/S.

Profitability

This table compares Demant A/S and Flora Growth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Demant A/S	N/A	N/A	N/A
Flora Growth	-32.03%	-64.02%	-34.46%

Risk and Volatility

Demant A/S has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.

Institutional & Insider Ownership

36.0% of Flora Growth shares are held by institutional investors. 2.3% of Flora Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Demant A/S and Flora Growth”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Demant A/S	$3.48 billion	2.10	$233.91 million	N/A	N/A
Flora Growth	$57.61 million	0.14	-$15.91 million	($32.49)	-0.23

Demant A/S has higher revenue and earnings than Flora Growth.

Summary

Demant A/S beats Flora Growth on 8 of the 13 factors compared between the two stocks.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.